Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bat-Sheva Maslow is active.

Publication


Featured researches published by Bat-Sheva Maslow.


Contraception | 2014

Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer.

Bat-Sheva Maslow; Christopher B. Morse; A. Schanne; Alison W. Loren; Susan M. Domchek; Clarisa R. Gracia

OBJECTIVE Few data on contraceptive choices in women with cancer exist. Contraception is challenging for women with cancer, particularly those with breast cancer, who are limited to nonhormonal methods. This study characterized contraceptive use during cancer treatment in a group of reproductive-aged women with a recent cancer diagnosis and assessed the impact of contraceptive counseling on the methods they selected. STUDY DESIGN Cross-sectional, survey study of reproductive-aged women at a large tertiary care health system with a recent cancer diagnosis. RESULTS A total of 107 women completed the survey. Eighty-two women reported 101 contraceptive choices. Twenty-seven percent (27/101) of all methods selected were Tier I/II, and 35% (35/101) were Tier III/IV. Only 4 used an intrauterine device (IUD). Among women reporting sexual activity after diagnosis, 19 (27%) of 71 reported using Tier I/II methods, 21 (30%) of 71 reported using Tier III/IV methods, 16 (23%) of 71 reported abstinence and 10 (14%) of 71 reported using no method. Factors significantly associated with Tier I/II use in the multivariable model included not having a college degree [odds ratio (OR) 0.21, 95% confidence interval (CI) 0.05-0.92, p=.038], intercourse during treatment (OR 5.92, 95% CI 1.48-23.66, p=.012) and non-breast cancer (OR 3.60, 95% CI 1.03-12.64, p=.046). Report of contraceptive counseling was positively associated with Tier I/II contraceptive use during cancer treatment (OR 6.92, 95% CI 1.14-42.11, p=.036). CONCLUSION Reproductive-aged women diagnosed with cancer underutilized Tier I/II contraceptive agents, especially IUDs. Contraceptive counseling by physicians increases contraceptive use, particularly methods most effective at preventing pregnancy. IMPLICATIONS The study uniquely described the contraceptive practices of over 100 women with cancer. The study sample commonly reported abstinence and use of contraceptive methods with high failure rates. Our data suggest that contraceptive counseling from a health care provider may increase use of more effective methods among women with cancer.


Journal of Assisted Reproduction and Genetics | 2016

Correlation of normal-range FMR1 repeat length or genotypes and reproductive parameters

Bat-Sheva Maslow; Stephanie Davis; L. Engmann; J. Nulsen; C.A. Benadiva


Fertility and Sterility | 2017

Increasing awareness of age-related fertility and elective fertility preservation among medical students and house staff: a pre- and post-intervention analysis

Erica Anspach Will; Bat-Sheva Maslow; L.A. Kaye; J. Nulsen


Fertility and Sterility | 2016

Prospective double-blind randomized placebo controlled clinical trial comparing pregnancy rates after co-administration of low dose HCG at the time of GnRH-agonist trigger or 35 hours later, for the prevention of OHSS

Bat-Sheva Maslow; Daniel Griffin; C.A. Benadiva; J. Nulsen; L. Engmann


Journal of Assisted Reproduction and Genetics | 2014

Concurrent ovarian and ipsilateral tubal ectopic pregnancies after a double embryo transfer: a case report.

Carolina Sueldo; Tara Budinetz; Bat-Sheva Maslow; J. Nulsen; L. Engmann; C.A. Benadiva


Fertility and Sterility | 2016

Optimal timing of frozen embryo transfer in natural cycles based on monitoring the ovulatory surge

Erica Anspach Will; Bat-Sheva Maslow; L.A. Kaye; C.A. Benadiva; L. Engmann; J. Nulsen


Fertility and Sterility | 2016

Old habits die hard: use of corticosteroids and antibiotics prior to embryo transfer

L.A. Kaye; C.B. Bartels; A. Bartolucci; Bat-Sheva Maslow; J. Nulsen; C.A. Benadiva


Fertility and Sterility | 2016

Occult abnormal pregnancies after first post-embryo transfer serum beta-human chorionic gonadotropin levels of 1.0-5.0 mIU/mL

Bat-Sheva Maslow; Alison Bartolucci; C.M. Sueldo; L. Engmann; C.A. Benadiva; J. Nulsen


Fertility and Sterility | 2015

Luteal phase luteinizing hormone (LH) levels after gonadotropin-releasing hormone agonist (GNRH-a) trigger and probability of conception

Chantal Bartels; Bat-Sheva Maslow; E. Anspach; C.A. Benadiva; J. Nulsen; L. Engmann


Fertility and Sterility | 2015

Elective embryo cryopreservation after prolonged premature progesterone elevation to improve in vitro fertilization (IVF) pregnancy outcomes

E. Anspach; Bat-Sheva Maslow; A. Bartolucci; C.A. Benadiva; J. Nulsen; L. Engmann

Collaboration


Dive into the Bat-Sheva Maslow's collaboration.

Top Co-Authors

Avatar

J. Nulsen

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

C.A. Benadiva

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar

L. Engmann

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar

A. Bartolucci

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

L.A. Kaye

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar

Tara Budinetz

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

A. Schanne

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Alison W. Loren

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

C.M. Sueldo

University of Connecticut

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge